ALMS ALUMIS INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1847367 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-72.6%
TTM EPS YoY-64.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-6,116.7%
Net margin-5,844.5%
FCF margin-4,433.3%
EBITDA margin-6,069.2%
Returns
ROE-110.9%
ROA-86.6%
ROIC (approx.)-109.3%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets22.6%
Debt / equity0.00x
Current ratio5.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-21.1%
Payout ratio—
Capex / revenue11.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.91M | $1.66M | $1.74M | $1.93M | $2.07M | $2.67M | $17.39M | — |
| R&D expense | $80.79M | $85.34M | $81.54M | $82.78M | $97.84M | $108.75M | $96.62M | $87.20M |
| SG&A expense | $20.19M | $23.36M | $18.61M | $15.59M | $19.52M | $34.45M | $22.30M | $11.42M |
| Operating income | -$99.08M | -$148.85M | -$98.41M | -$96.44M | -$115.29M | -$140.54M | -$101.53M | -$98.62M |
| Pretax income | -$94.88M | -$143.98M | — | -$92.93M | -$110.75M | $50.76M | — | -$94.76M |
| Income tax | $0 | -$1.76M | — | $0 | $0 | -$8.60M | — | $0 |
| Net income | -$94.88M | -$142.22M | -$93.05M | -$92.93M | -$110.75M | $59.32M | -$98.96M | -$94.76M |
| EBITDA | -$98.18M | -$148.06M | -$97.54M | -$95.58M | -$114.39M | -$139.64M | -$100.69M | -$97.80M |
| EPS (basic) | -0.73 | -1.11 | -0.74 | — | -1.06 | 0.78 | -1.82 | — |
| EPS (diluted) | -0.73 | -1.11 | -0.74 | — | -1.06 | 0.77 | -1.82 | — |
| Weighted avg. shares (diluted) | 129.29M | 127.69M | 125.05M | — | 104.11M | 76.64M | 65.44M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $57.69M | $63.71M | $63.88M | $89.67M | $65.26M | $151.75M | $128.54M | $170.63M |
| Short-term investments | — | — | — | $218.83M | $312.47M | $334.57M | $80.21M | $118.74M |
| Current assets | $442.59M | $514.08M | $532.41M | $318.23M | $393.29M | $517.56M | $225.53M | $306.19M |
| PP&E, net | $16.43M | $16.85M | $17.53M | $18.19M | $19.06M | $20.33M | $20.33M | $20.97M |
| Total assets | $488.71M | $560.62M | $671.59M | $411.94M | $488.01M | $610.92M | $261.30M | $340.99M |
| Current liabilities | $79.41M | $76.23M | $70.90M | $73.32M | $65.42M | $85.58M | $60.45M | $50.91M |
| Total liabilities | $110.29M | $108.46M | $104.57M | $110.64M | $103.24M | $125.60M | $92.98M | $80.89M |
| Shareholders' equity | $378.43M | $452.16M | $567.02M | $301.30M | $384.77M | $485.33M | $168.31M | $260.10M |
| Cash flow statement | ||||||||
| Operating cash flow | -$79.57M | -$81.50M | -$87.08M | -$71.91M | -$110.91M | -$106.35M | -$80.36M | -$74.76M |
| Capital expenditure | $464,000 | $237,000 | $164,000 | $0 | $0 | $616,000 | $37,000 | $366,000 |
| Free cash flow | -$80.03M | -$81.74M | -$87.25M | -$71.91M | -$110.91M | -$106.97M | -$80.39M | -$75.13M |
| Investing cash flow | $65.94M | $68.69M | -$285.69M | $95.01M | $24.04M | $129.40M | $39.43M | $30.95M |
| Financing cash flow | $7.61M | $12.63M | $346.99M | $1.32M | $0 | — | — | $5,000 |
| Depreciation & amortization | $900,000 | $800,000 | $871,000 | $867,000 | $900,000 | $900,000 | $843,000 | $820,000 |
| Stock-based compensation | $14.29M | $14.27M | $12.34M | $8.11M | $9.79M | $18.64M | $7.00M | $6.36M |
| Share buybacks | — | — | — | $0 | $0 | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.